|
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) |
|
Acadia Pharmaceuticals Inc
ACAD's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Acadia Pharmaceuticals Inc growth rates, revenue grew
by 18.28 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 488
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Acadia Pharmaceuticals Inc realized net income compared to net loss a year ago in III. Quarter 2024
• More on ACAD's Growth
|
|
Acadia Pharmaceuticals Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Acadia Pharmaceuticals Inc PEG ratio is at -0.15
Company is currently trading with Price to Cash flow multiple of 51.41 in trailing twelve-month period. |
Company |
26.19 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.32.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.
• More on ACAD's Valuation
|
|
|
|
|
Acadia Pharmaceuticals Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Acadia Pharmaceuticals Inc PEG ratio is at -0.15
Company is currently trading with Price to Cash flow multiple of 51.41 in trailing twelve-month period. |
Company |
26.19 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.32.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.
Acadia Pharmaceuticals Inc Price to Book Ratio is at 5.34 lower than Industry Avg. of 88.81. and higher than S&P 500 Avg. of 0.02
• More on ACAD's Valuation
|
|
ACAD's Profitability Comparisons
|
Acadia Pharmaceuticals Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 12.64 % from 12.58 % in II. Quarter.
Acadia Pharmaceuticals Inc net profit margin of 13.09 % is currently ranking no. 39 in Major Pharmaceutical Preparations industry, ranking no. 91 in Healthcare sector and number 1074 in S&P 500.
Profitability by Segment |
Total |
13.09 % |
|
|
Acadia Pharmaceuticals Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 12.64 % from 12.58 % in II. Quarter.
Acadia Pharmaceuticals Inc net profit margin of 13.09 % is currently ranking no. 39 in Major Pharmaceutical Preparations industry, ranking no. 91 in Healthcare sector and number 1074 in S&P 500.
• More on ACAD's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com